Sugi Predict

Sugi Predict / Compounds / SCHEMBL3237373

SCHEMBL3237373

SCHEMBL3237373

CC(C)[Si](OC(N)=O)(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ ALOX15 P16050 2/20 0.32
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNB4 P30926 1/20 0.31
▸ CHRNA3 P32297 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31
▸ BLM P54132 1/20 0.30
▸ PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22557953 0.79 TSHR (0.32) TSHR
SCHEMBL475861 0.74 TSHR (0.41) CHRM2CHRM4CHRM1TSHRMAPT
SCHEMBL22557955 0.74 TP53 (0.33) —
SCHEMBL3237366 0.74 LMNA (0.31) LMNACHRM2CHRM4CHRM5CHRM1
SCHEMBL475860 0.72 — —
SCHEMBL6514742 0.72 ELANE (0.31) —
SCHEMBL22557916 0.70 TSHR (0.43) LMNACYP2C9TSHRMAPTPMP22
SCHEMBL22557951 0.70 TSHR (0.43) LMNATSHR
SCHEMBL5974692 0.70 HCAR2 (0.39) —
SCHEMBL15843417 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138946-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB CURIA SPAIN S A U (ES) 2026-05-21 — — US disclosed
US-12552746-B2 Process and intermediates for the preparation of upadacitinib CURIA SPAIN, S.A.U. (ES) 2026-02-17 — — US disclosed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 — — EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 — — US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 — — US disclosed
CN-115151529-B Processes and intermediates for preparing Wu Pati n 库里亚西班牙公司 2025-04-22 — — CN disclosed
WO-2025077996-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2025-04-17 — — WO disclosed
EP-4419513-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2024-08-28 — — EP disclosed
US-20240166666-A1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-05-23 — — US disclosed
US-20240131180-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2024-04-25 — — US disclosed
US-10442820-B2 — — 2019-10-15 — — US disclosed
US-20180312529-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2018-11-01 — — US disclosed
WO-2018197663-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2018-11-01 — — WO disclosed
US-9969739-B2 Tricyclic chiral compounds and their use in asymmetric catalysis NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2018-05-15 — — US disclosed
US-20160207932-A1 NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS UNIV NANYANG TECH (SG) 2016-07-21 — — US disclosed
US-8748388-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2014-06-10 — — US disclosed
US-20100292163-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2010-11-18 — — US disclosed
WO-2010027334-A1 NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2010-03-11 — — WO disclosed
EP-1214326-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2002-06-19 — — EP disclosed
WO-2001018006-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138946-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB JAK1, JAK3, JAK2 LMNA 750/4885CHRM2 3173/4885CHRM4 3306/4885
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 LMNA 1898/4885CHRM2 4849/4885CHRM4 4874/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB LMNA 1550/4885CHRM2 4842/4885CHRM4 4844/4885
US-20240131180-A1 DRUG ANTIBODY CONJUGATES STT3B, STT3A, TTL LMNA 1254/4885CHRM2 4323/4885CHRM4 4189/4885
US-20100292163-A1 Antitumoral Compounds TP53, XPO1, TOP2B LMNA 3075/4885CHRM2 4848/4885CHRM4 4878/4885
US-10442820-B2 — RPS4X, RPS4Y1, XPOT LMNA 2072/4885CHRM2 1053/4885CHRM4 1251/4885
US-12552746-B2 Process and intermediates for the preparation of upadacitinib JAK1, JAK3, MET LMNA 602/4885CHRM2 3312/4885CHRM4 3630/4885
US-20160207932-A1 NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS COX6C, CBR3, CYCS LMNA 2287/4885CHRM2 56/4885CHRM4 32/4885
US-20240166666-A1 ANTITUMORAL COMPOUNDS TP53, TOP1, MCL1 LMNA 1898/4885CHRM2 4849/4885CHRM4 4874/4885
US-20180312529-A1 Antitumoral Compounds TP53, RB1, XPOT LMNA 2420/4885CHRM2 2651/4885CHRM4 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.